A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

NCT04149587 · clinicaltrials.gov ↗

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Brodalumab

Sponsor

Bausch Health Americas, Inc.